Surgical cytoreduction for recurrent epithelial ovarian cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ayhan, 2006, The role of secondary cytoreduction in the treatment of ovarian: Hacettepe University experience, American Journal of Obstetrics and Gynaecology, 194, 49, 10.1016/j.ajog.2005.06.048
Chi, 2006, Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma, Cancer, 106, 1933, 10.1002/cncr.21845
Eisenkop, 2000, The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma, Cancer, 88, 144, 10.1002/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X
Harter, 2006, Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial, Annals of Surgical Oncology, 13, 1702, 10.1245/s10434-006-9058-0
Oksefjell, 2009, The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer, Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 20, 286, 10.1093/annonc/mdn591
Salani, 2007, Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer, Cancer, 109, 685, 10.1002/cncr.22447
Scarabelli, 2001, Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma, Gynecologic Oncology, 83, 504, 10.1006/gyno.2001.6404
Tian, 2010, Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1 - 1 cm after secondary cytoreduction, Journal of Surgical Oncology, 101, 244, 10.1002/jso.21491
Zang, 2000, Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer, Journal of Surgical Oncology, 75, 24, 10.1002/1096-9098(200009)75:1<24::AID-JSO5>3.0.CO;2-L
Benedetti Panici, 2006, Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer, Annals of Surgical Oncology, 14, 1136, 10.1245/s10434-006-9273-8
Berek, 1983, Survival of patients following secondary cytoreductive surgery in ovarian cancer, Obstetrics & Gynecology, 61, 189
Bristow, 2003, Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT, Gynecologic Oncology, 90, 519, 10.1016/S0090-8258(03)00336-6
Bristow, 2009, Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome, Gynecologic Oncology, 114, 173, 10.1016/j.ygyno.2009.05.004
Eisenkop, 1995, Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study, Cancer, 76, 1606, 10.1002/1097-0142(19951101)76:9<1606::AID-CNCR2820760917>3.0.CO;2-H
Gadducci, 2000, Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer, Gynecologic Oncology, 79, 344, 10.1006/gyno.2000.5992
Goto, 2011, Potential survival benefit of secondary cytoreductive surgery for recurrent epithelial ovarian, tubal, and peritoneal cancers, International Journal of Gynecological Cancer, 21, 263, 10.1097/IGC.0b013e3182098002
Gronlund, 2005, Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum, European Journal of Surgical Oncology, 31, 67, 10.1016/j.ejso.2004.08.016
Gungor, 2005, The role of secondary cytoreductive surgery for recurrent ovarian cancer, Gynecologic Oncology, 97, 74, 10.1016/j.ygyno.2004.11.057
Helm, 2007, Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma, Gynecologic Oncology, 105, 90, 10.1016/j.ygyno.2006.10.051
Karam, 2007, Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome, Gynecologic Oncology, 104, 377, 10.1016/j.ygyno.2006.08.037
Landoni, 1998, Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy, Acta Obstetricia et Gynecologica Scandinavica, 77, 233
Matsumoto, 2006, Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy, The Journal of Obstetrics and Gynaecology Research, 32, 580, 10.1111/j.1447-0756.2006.00460.x
Morris, 1989, Secondary cytoreductive surgery for recurrent epithelial ovarian cancer, Gynecologic Oncology, 34, 334, 10.1016/0090-8258(89)90168-6
Munkarah, 2001, Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer, Gynecologic Oncology, 81, 237, 10.1006/gyno.2001.6143
Park, 2006, The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns, Gynecologic Oncology, 103, 977, 10.1016/j.ygyno.2006.06.004
Tay, 2002, Secondary cytoreductive surgery for recurrent epithelial ovarian cancer, Obstetrics and Gynecology, 99, 1008
Tebes Stephen, 2007, Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma, Gynecologic Oncology, 106, 482, 10.1016/j.ygyno.2007.04.006
Vaccarello, 1995, Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response, Gynecologic Oncology, 57, 61, 10.1006/gyno.1995.1099
Vange, 2000, Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot, European Journal of Surgical Oncology (EJSO), 26, 663, 10.1053/ejso.2000.0978
Zang, 2000, Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer, European Journal of Surgical Oncology (EJSO), 26, 798, 10.1053/ejso.2000.1007
Zang, 2003, Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: a retrospective case-control study, International Journal of Gynecological Cancer, 13, 419, 10.1136/ijgc-00009577-200307000-00004
Zang, 2004, Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?, Cancer, 100, 1152, 10.1002/cncr.20106
Zanon, 2004, Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer, World Journal of Surgery, 28, 1040, 10.1007/s00268-004-7461-x
Boente, 1998, The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery, Seminars in Oncology, 25, 326
Bookman, 1998, Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel, Journal of Clinical Oncology, 16, 3345, 10.1200/JCO.1998.16.10.3345
Bristow, 2002, Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis, Journal of Clinical Oncology, 20, 1248, 10.1200/JCO.2002.20.5.1248
Burke, 1994, Secondary cytoreductive surgery for ovarian cancer, Obstetrics and Gynecology Clinics of North America, 21, 167, 10.1016/S0889-8545(21)00314-4
Common Terminology Criteria for Adverse Events v3.0 www.eortc.be/services/doc/ctc/ctcaev3.pdf
Deeks, 2001, Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis, Systematic Reviews in Health Care: Meta-Analysis in Context, 10.1002/9780470693926.ch15
Delgado, 1984, Stage III epithelial ovarian cancer: the role of maximal surgical reduction, Gynecologic Oncology, 18, 293, 10.1016/0090-8258(84)90040-4
DerSimonian, 1986, Meta-analysis in clinical trials, Controlled Clinical Trials, 7, 177, 10.1016/0197-2456(86)90046-2
Elattar, 2011, Optimal primary surgical treatment for advanced epithelial ovarian cancer, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD007565.pub2
Sant, 2003, EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary, Annals of Oncology, 14 Suppl 5, v61, 10.1093/annonc/mdg754
Galaal, 2010, Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD007822.pub2
Ferlay J Shin HR Bray F Forman D Mathers C Parkin DM GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide globocan.iarc.fr
Goff, 2000, Ovarian carcinoma diagnosis, Cancer, 89, 2068, 10.1002/1097-0142(20001115)89:10<2068::AID-CNCR6>3.0.CO;2-Z
Gonzalez-Martin, 2003, Randomized phase II study of carboplatin versus paclitaxel-carboplatin in platinum sensitive recurrent advanced ovarian carcinoma with assessment of quality of life, Proceedings of the American Society of Clinical Oncology, 22, abs 1812
Hacker, 1983, Primary cytoreductive surgery for epithelial ovarian cancer, Obstetrics and Gynecology, 61, 413
Hannibal, 2008, Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five year relative survival, Acta Obstetricia et Gynecologica Scandinavica, 87, 1353, 10.1080/00016340802483000
Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated September 2008]. The Cochrane Collaboration, 2008 Available from www.cochrane-handbook.org
Hoskins, 1994, The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with sub optimal residual epithelial ovarian carcinoma, American Journal of Obstetrics and Gynecology, 70, 974, 10.1016/S0002-9378(94)70090-7
Parkin DM Whelan SL Ferlay J Teppo L Thomas DB Cancer Incidence in Five Continents, Volume VIII IARC Scientific Publication 2002; No. 155 2002
Jemal, 2008, Cancer statistics, CA: A Cancer Journal for Clinicians, 58, 71
Markman, 2004, Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design, Journal of Clinical Oncology, 22, 3120, 10.1200/JCO.2004.05.195
Munkarah, 2004, Critical evaluation of secondary cytoreduction in recurrent ovarian cancer, Gynecologic Oncology, 95, 273, 10.1016/j.ygyno.2004.09.018
Ozols, 2005, Epithelial ovarian cancer, Principles and Practice of Gynecologic Oncology, 895
Parmar, 1998, Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, Statistics in Medicine, 17(24), 2815, 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
Parmar, 2003, Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer. the ICON4/AGO-OVAR-2-2 trial, Lancet, 361, 2099, 10.1016/S0140-6736(03)13718-X
Piver, 1988, The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in Stage III and IV ovarian carcinoma, Journal of Clinical Oncology, 6, 983, 10.1200/JCO.1988.6.6.983
The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011
Scully, 1998, Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament, Atlas of Tumor Pathology, Fascicle 23 3rd, 1
Shepherd, 1989, Revised FIGO staging for gynaecological cancer, British Journal of Obstetrics and Gynaecology, 96, 889, 10.1111/j.1471-0528.1989.tb03341.x
Smith, 2005, Ovarian cancer: can we make the clinical diagnosis earlier?, Cancer, 104, 1398, 10.1002/cncr.21310
Vergote, 2011, Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer, European Journal of Cancer, 47 Suppl 3, S88, 10.1016/S0959-8049(11)70152-6